The Series B conversion creates significant overhang; expect downward pressure on the stock as the new shares enter the market. However, the company's strong cash runway (~$200M) and upcoming PIKTOR Phase 2 data in H2 2026 provide a potential catalyst. Monitor trading under the new ticker FTH for volume and price discovery.
Price Chart
Executive Summary
Sensei Biotherapeutics (SNSE) filed an 8-K confirming its name change to Faeth Therapeutics (ticker FTH effective June 16), the termination of its $50M ATM facility (no shares sold), and the appointment of a new leadership team including Anand Parikh as CEO and Brian Stephenson as CFO. The filing also confirms the conversion of Series B preferred stock into common stock, adding ~24.4M shares to the float, which was approved by stockholders on June 10. While the company holds ~$200M in gross proceeds from the February PIPE, the massive dilution from the Series B conversion is a material negative for existing common holders.
Key Facts
- Company name changed to Faeth Therapeutics, Inc.; ticker changes to FTH on June 16, 2026.
- Terminated the $50M ATM sales agreement with Jefferies; no shares were ever sold under it.
- Anand Parikh appointed Chairman, President and CEO; Brian Stephenson appointed CFO.
- Series B preferred stock conversion approved, adding ~24.4M shares to common float (pro forma share count ~25.7M vs 1.3M actual).
- Board reduced from 6 to 5 members; former FDA Commissioner Stephen Hahn and Saira Ramasastry appointed as directors.
- PIKTOR Phase 2 topline data in advanced endometrial cancer expected H2 2026; interim Phase 1b/2 breast cancer data expected 2027.
- Principal executive office relocated from Rockville, MD to Austin, TX.
Financial Impact
Massive dilution: Series B conversion adds ~24.4M shares to a prior float of ~1.3M shares. Company holds ~$200M in gross proceeds from the February PIPE.
Risk Factors
- Massive dilution from Series B conversion could depress share price.
- Clinical trial risk: PIKTOR Phase 2 data may not meet endpoints.
- Integration risk from the Faeth acquisition and leadership transition.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-270330 |
| Document: d144622dex991.htm | 0001193125-26-270330 |
| Document: d144622dex31.htm | 0001193125-26-270330 |
| Document: 0001193125-26-270330-index-headers.html | 0001193125-26-270330 |
| Document: 0001193125-26-270330-index.html | 0001193125-26-270330 |
| Document: 0001193125-26-270330.txt | 0001193125-26-270330 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 16, 2026 18w ago | 3 | $13.86 | awaiting T+5 | — | — |
Jun 15, 2026 19w ago | 8-K | $13.04 | awaiting T+5 | — | — |
Jun 15, 2026 19w ago | EFFECT | $13.04 | awaiting T+5 | — | — |
Jun 10, 2026 19w ago | S-3/A | $10.79 $13.85 | ▲ +28.36% | ▲ +27.93% | — |
Jun 10, 2026 19w ago | 8-K | $10.79 $13.85 | ▲ +28.36% | ▲ +27.93% | — |
Jun 2, 2026 21w ago | 10-K/A | $16.10 $12.63 | ▼ −21.53% | ▼ −18.56% | — |
Jun 2, 2026 21w ago | S-3/A | $16.10 $12.63 | ▲ +21.53% | ▲ +18.56% | — |
Jun 1, 2026 21w ago | Insider Cluster | $16.10 $12.63 | ▲ +21.53% | ▲ +18.56% | — |
May 22, 2026 22w ago | DEFA14A | $16.47 $19.79 | ▲ +20.16% | ▲ +19.07% | — |
May 22, 2026 22w ago | 8-K | $16.47 $19.79 | ▲ +20.16% | ▲ +19.07% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers